Opendata, web and dolomites

ULISENS

Ultra Legionella Inmunoanalysis System for Early Sensing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ULISENS" data sheet

The following table provides information about the project.

Coordinator
BIOTICA BIOQUIMICA ANALITICA SL 

Organization address
address: PARQUE CIENTIFICO TECNOLOGICO Y EMPRESARIAL UNIVERSIDAD JAUME I CAMPUS RIU SEC AV SOS BAYNAT ED ESP
city: CASTELLON
postcode: 12071
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.biotica.es/en
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2015-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOTICA BIOQUIMICA ANALITICA SL ES (CASTELLON) coordinator 50˙000.00

Map

 Project objective

The general objective of ULISENS project will be focused on the commercial development and further commercialization of an automatic early warning system able to detect and quantify Legionella species in water. The system integrates an innovative fast detection automatic module able to carry out “in situ” analysis in real-time based on information and communication technologies to minimise the time for obtaining results. ULISENS will have the following functionalities: - Faster response time, with a time reduction of up to 99% compared with standard laboratory tests (1h vs 288h) - Greater reliability thanks to the certified detection and enumeration technology (accuracy of detection higher than 99%) - Lower cost, with reductions of up to 84% compared with standard laboratory tests (8€ per test vs 50€ per test) - Direct sampling from user’s network in real-time, no technical staff needed. - Sustainable detection biotechnology without maintenance - No hazardous waste generation (no biological waste) - Customizable online early warning module with internet connection to prevent users from risk.

Apart from the previous technological objectives, ULISENS has also the following specific objectives: - To develop a business and exploitation plan, including the assessment of the cost‐effectiveness and exploitation potential of the solution. - To tackle main bottlenecks and barriers for the full commercialization of the innovative technologies, mainly related to legislative and regulatory aspects in each country. - To widely disseminate project outcomes to stakeholders and end‐users, strengthening synergies with other initiatives and platforms to reach the maximum impact. - To analyse market and business strategies in the sector in order to find the best combination of external agents and international entities to develop cooperation strategies for market exploitation and further products commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ULISENS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ULISENS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More